You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2020 to November 2024

AbstractFullPdf
Nov 2020374060
Dec 202061047
Jan 202156022
Feb 202182032
Mar 2021122022
Apr 2021112026
May 202144025
Jun 20210023
Jul 20210018
Aug 20210033
Sep 20210025
Oct 2021126032
Nov 2021118026
Dec 2021110019
Jan 20224606
Feb 2022114012
Mar 20227608
Apr 2022102018
May 2022118014
Jun 202270010
Jul 2022102010
Aug 2022100020
Sep 20225409
Oct 20225408
Nov 202264010
Dec 20227404
Jan 20236007
Feb 20239809
Mar 20239807
Apr 20236609
May 20237607
Jun 20237006
Jul 202378018
Aug 202392015
Sep 20236602
Oct 20235404
Nov 20236007
Dec 20238206
Jan 20243601
Feb 20244001
Mar 20248404
Apr 20246408
May 20246006
Jun 20247802
Jul 20245204
Aug 20242808
Sep 20243405
Oct 202440017
Nov 20246607
Total36610699